Tockman et al., Cancer Res., 1992, 52:2711s-2718s.* |
Kraus et al., Jnl. of Immunoassay, v13 (3), 1992, pp. 411-439.* |
Miyachi et al., “Autoantibody to a Nuclear Antigen in Proliferating Cells”, vol. 121, No. 6, Dec. 1978, pp. 2228-1134. |
Bachvaroff et al., “Appearance of cytoskeletal components on the surface of leukemia cells and oflymphocytes transformed by mitogens and Epstein-Barr virus”, Proc. Natl. Acad. Sci. USA, vol. 77, No. 8, Aug. 1980,pp. 4979-4983. |
Crawford et al., “Detection of Antibodies Against the Cellular Protein p53 In Sera from Patients with Breast Cancer”, Int. J. Cancer 30, 1982, pp. 403-408. |
Wallner et al., “Cloning and expression of human lipocortin, a phospholipase A2 inhibitor with potential anti-inflammatory activity”, Nature, vol. 320, Mar. 1986, pp. 77-80. |
Weber et al., “Repeating sequence homologies in the p36 target protein of retroviral protein kinses and lipocortin, the p37 inhibitor of phospholipase A2”, FEBS LETTERS, vol. 203, No. 1, Jul. 1986, pp. 95-98. |
Saris et al, “The cDNA Sequence for the Protein-Tyrosine Kinase Substrate p36 (Calpactin 1 Heavy Chain) Reveals a Multidomain Protein with Internal Repeats”, Cell, vol. 46, Jul. 18, 1986, pp. 201-212. |
Huang et al., “Two Human 35 kd Inhibitors of Phospholipase A2 Are Related to Substrates of pp60v-src and of the Epidermal Growth Factor Receptor/Kinase”, Cell, vol. 46, Jul. 18, 1986, pp. 191-199. |
Tan et al., “PCNA/Cyclin: A Lupus Antigen Connected with DNA Replication”, J. Rheumatol., Supp. 13, vol. 14, 1987, pp. 89-96. |
Ben-Mahrez et al., “Circulating Antibodies Against C-MYC Oncogene Product in Sera of Colorectal Cancer Patients”, Int. J. Cancer 46, 1990, pp. 35-38. |
Sorokine et al., “Presence of Circulating Anti-c-myp Oncogene Product Antibodies in Human Sera”, Int. J. Cancer: 47, 1991, pp. 665-669. |
Bandorowicz et al., “Annexins—multifunctional, calcium-dependent phosphloipid-binding proteins”, Acta Biochimica Polonica, vol. 40, No. 3, 1993, pp. 281-293. |
Swairjo et al., “Annexin Structure and Mebrance Interactions: A Molecular Perspective”, Annu. Rev. Biophys. Biomol. Struct. 23, 1994, pp. 193-213. |
Mao et al., “Detection of Oncogene Mutations in Sputum Precedes Diagnosis of Lung Cancer”, Cancer Res. 54, Apr. 1, 1994, pp. 1634-1637. |
Liemann et al., “Annexins: a novel family of calcium- and membrane- binding proteins in search of a function”, Structure, vol. 3, No. 3, 1995, pp. 233-237. |
Gourevitch et al., “Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patietns”, Br. J. Cancer 72, 1995, pp. 934-938. |
Mills et al., “Detection of K-ras Oncogene Mutations in Bronchoalveolar Lavage Fluid for Lung Cancer Diagnosis”, J. Natl. Cancer Inst., vol. 87, No. 14, Jul. 19, 1995, pp. 1056-1060. |
Takahashi et al., “Antibody to ras Proteins in Patients with Colon Cancer”, Clin. Cancer Res., vol. 1, Oct. 1995, pp. 1071-1077. |
Peyrate et al., “Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer”, Lancet, vol. 345, Mar. 1, 1995, pp. 621-622. |
Lubin et al., “Serum p53 antibodies as early markers of lung cancer”, Nat. Med., vol. 1, No. 7, Jul. 1995, pp. 701-702. |
Yamamoto et al., “Detection of auto-antibodies against L-myc Oncogene Products in Sera From Lung Cancer Patients”, J. Int. Cancer (Pred. Oncol) 69, 1996, pp. 283-289. |
Soussi, “The humoral response to the tumor-suppressor gene product p53 in human cancer: implications for diagnosis and therapy”, Immunol. Today, vol. 17, No. 8, pp. 354-356. |
Travis et al., “United States Lung Carcinoma Incidence Trends”, Cancer, vol. 77, No. 12, Jun. 15, 1996, pp. 2464-2470. |
Benz et al., “Annexins: From Structure to Function”, Biol. Chem., vol. 378, Mar./Apr. 1997, pp. 177-183. |
Gerke et al., “Annexins and membrane dynamics”, Biochemica et Biophysica Acta 1357, 1997, pp. 129-154. |
Donnelly et al., “Annexins in the secretory pathway”, Cell Mol. Life Sci. 53, 1997, pp. 533-538. |
Mollenhuaer, “Annexins: what are they good for?”, Cell Mol. Life Sci. 53, 1997, pp. 506-507. |
Gao et al., “Distribution of p53 and K-ras mutations in human lung cancer tissues”, Carcinogenesis, vol. 18, No. 3, 1997, pp. 473-478. |
Old et al., “New Paths in Human Cancer Serology”, J.Exp. Med., vol. 187, No. 8, Apr. 20, 1998, pp. 1163-1167. |
Iizasa et al., “Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma”, Cancer Immunol. Immunother. 46, 1998, pp. 345-349. |
Stockert et al., “A survey of the humoral ammune response of cancer patients to a panel of human tumor antigens”, J. Exp. Med. 187, 1998, pp. 1349-1354. |
Güre et al., “Human Lung Cancer Antigens Recognized by Autologous Antibodies: Definition of a Novel cDNA Derived from the Tumor Suppressor Gene Locus on Chromosome 3p21.3”, Cancer Res. 58, Mar. 1, 1998, pp. 1034-1041. |
Cawley et al., “Anti-p53 Antibodies in Patients with Barrett's Esophagus or Esophagael Carcinoma Can Predate Cancer Diagnosis”, Gastroenterology, vol. 115, No. 1, 1998, pp. 19-27. |
Pencil et al., Elevated Levels of Annexin I Protein in Vitro and In Vivo in Rat and Human Mammary Adenocarcinoma, 1998, Clin. Exp. Metastasis 16:113-121. |
Davis et al., Detection of Secreted and Intracellular Annexin II by a Radiommunoassay, 1995, Journal of Immunological Methods 188:91-95. |
Tsao et al., Annexin I in Female Rabbit Reproductive Organs: Varying Levels in Relation to Maturity and Pregnancy, 1995, Lipids 30:507-511. |
William et al, Differentiation of HL-60 Cells is Associated with an Increase in the 35-KDa Protein Lipocortin I, 1988, J. Cellular Physiology 137:402-410. |